Loading…
Autolus Therapeutics plc is projected to rise to $1.65 by 2027, a +11% move from its current price of $1.49. AUTL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.44 | $1.49 | $1.54 | -0.05% |
| Aug 4 | $1.42 | $1.49 | $1.56 | -0.10% |
| Aug 5 | $1.41 | $1.49 | $1.57 | -0.15% |
| Aug 6 | $1.40 | $1.49 | $1.58 | -0.20% |
| Aug 7 | $1.39 | $1.49 | $1.59 | -0.26% |
| Aug 8 | $1.38 | $1.49 | $1.60 | -0.31% |
| Aug 9 | $1.37 | $1.48 | $1.61 | -0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.37 | $1.48 | $1.61 | -0.36% |
| Week 2 | $1.32 | $1.48 | $1.66 | -0.71% |
| Week 3 | $1.28 | $1.47 | $1.70 | -1.07% |
| Week 4 | $1.25 | $1.47 | $1.73 | -1.42% |
| Week 5 | $1.22 | $1.46 | $1.76 | -1.78% |
| Week 6 | $1.19 | $1.46 | $1.78 | -2.13% |
| Week 7 | $1.17 | $1.45 | $1.81 | -2.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Autolus Therapeutics plc is a healthcare company described as a clinical-stage biopharmaceutical firm that develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia.
The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc (AUTL) is a healthcare stock described as a clinical-stage biopharmaceutical company focused on T cell therapies for cancer and autoimmune diseases. The current price is $1.52 per share. The company has a market capitalization of $404.54M and is ranked 3139.
Forecasts show an overall upward price trajectory, with the average price rising to $2.60 by 2030 and to $8.62 by 2050, with max prices reaching $3.95 (2030), $9.10 (2040), and $17.31 (2050).
A major floor 18.8% below — a decisive break under it would weaken the trend.
The nearest floor, 6.0% below — buyers have tended to step in here.
The nearest ceiling, 14.1% above — a clean break opens room to run.
A major ceiling 25.5% above — clearing it would confirm fresh momentum.
Key AUTL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AUTL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.48 | Buy | $1.49 | Buy |
| MA 10 | $1.47 | Buy | $1.48 | Buy |
| MA 20 | $1.51 | Sell | $1.50 | Sell |
| MA 50 | $1.57 | Sell | $1.54 | Sell |
| MA 100 | $1.53 | Sell | $1.55 | Sell |
| MA 200 | $1.53 | Sell | $1.62 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.90 | Neutral |
| Stoch RSI (14) | 75.13 | Neutral |
| CCI (20) | -21.06 | Neutral |
| Williams %R (14) | -30.77 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -1.32 | Sell |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 69.23 | Neutral |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 55.17 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 1.49 | Sell |
| ADX (14) | 10.23 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50, indicating ambivalent momentum. The 50-day simple moving average is $1.59 and the 200-day simple moving average is $1.54. Support sits at $1.40 and resistance at $1.70, framing a near-term trading range.
The 30-day range spans from $1.22 to $1.90, reflecting limited intraday volatility within that window. Annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.21 | $1.49 | $1.93 | 0% | Neutral | |
| $1.30 | $1.65 | $2.22 | +11% | Neutral | |
| $1.49 | $1.96 | $2.75 | +31% | Bullish | |
| $1.69 | $2.27 | $3.30 | +53% | Bullish | |
| $1.81 | $2.50 | $3.73 | +68% | Bullish | |
| $1.80 | $2.54 | $3.88 | +70% | Bullish | |
| $1.78 | $2.56 | $4.00 | +72% | Bullish | |
| $1.79 | $2.63 | $4.19 | +77% | Bullish | |
| $2.05 | $3.07 | $4.97 | +106% | Bullish | |
| $2.54 | $3.87 | $6.37 | +160% | Bullish | |
| $2.88 | $4.75 | $8.36 | +219% | Bullish | |
| $4.38 | $8.31 | $16.15 | +458% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.21 | $1.49 | $1.82 | +0.00% |
| September 2026 | $1.24 | $1.47 | $1.80 | -1.54% |
| October 2026 | $1.19 | $1.42 | $1.76 | -3.07% |
| November 2026 | $1.22 | $1.47 | $1.84 | +3.51% |
| December 2026 | $1.26 | $1.53 | $1.93 | +3.65% |
Click any year to see its month-by-month AUTL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AUTL price prediction for 2026 points to an average of $1.49 (low $1.21, high $1.93) — a potential gain of 0% on today's $1.49. A consolidation phase looks the most probable path here.
In 2027, AUTL is projected to trade between $1.30 and $2.22, averaging $1.65 — a potential gain of +11% from today's $1.49. That is up +11% on the projected 2026 average. Price action looks broadly range-bound.
Autolus Therapeutics plc's 2028 outlook centres on $1.96, within a $1.49 to $2.75 range. That is up +19% on the projected 2027 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, AUTL could reach as high as $3.30, with a base case around $2.27 and support toward $1.69 — roughly +53% from $1.49. Momentum favours further upside here.
Expect AUTL to range from $1.81 to $3.73 through 2030. The $2.50 average target implies a +68% move from current prices. That is up +10% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The AUTL price prediction for 2031 points to an average of $2.54 (low $1.80, high $3.88) — a potential gain of +70% on today's $1.49. Momentum favours further upside here.
In 2032, AUTL is projected to trade between $1.78 and $4.00, averaging $2.56 — a potential gain of +72% from today's $1.49. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Autolus Therapeutics plc's 2033 outlook centres on $2.63, within a $1.79 to $4.19 range. That is up +3% on the projected 2032 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2034, AUTL could reach as high as $4.97, with a base case around $3.07 and support toward $2.05 — roughly +106% from $1.49. Buyers look set to stay in control over this stretch.
Expect AUTL to range from $2.54 to $6.37 through 2035. The $3.87 average target implies a +160% move from current prices. That is up +26% on the projected 2034 average. Momentum favours further upside here.
The AUTL price prediction for 2040 points to an average of $4.75 (low $2.88, high $8.36) — a potential gain of +219% on today's $1.49. Buyers look set to stay in control over this stretch.
In 2050, AUTL is projected to trade between $4.38 and $16.15, averaging $8.31 — a potential gain of +458% from today's $1.49. That is up +75% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in AUTL today (≈ 671.14094 AUTL) could be worth
$5,578.34
+$4,578.34 (+458%) by 2050 · US Dollar
Based on the average projected AUTL price of $8.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AUTLwould be worth at today's price.
$1,000 invested in AUTL on Jul 31, 2025 (≈ 416.66665 AUTL) would be worth
$620.83
-$379.17 (-37.9%) today · 0.62× · US Dollar
Based on a AUTL entry price of $2.4 vs. today's $1.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.45 | $1,027.59 | +2.8% |
| 1 month ago | $1.58 | $943.04 | -5.7% |
| 3 months ago | $1.47 | $1,013.61 | +1.4% |
| 6 months ago | $1.38 | $1,079.71 | +8.0% |
| 1 year ago | $2.4 | $620.83 | -37.9% |
| All time (5.0y) ago | $5.54 | $268.95 | -73.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AUTL forecast.
Our base-case forecast reaches $3.00 around 2034.
Implied market cap at $3.00: $798.43M
Looking across the multi-year forecast, the average price progresses from $1.52 in 2026 to $2.60 in 2030, $5.02 in 2040, and $8.62 in 2050. The corresponding 2030 max is $3.95, 2040 max is $9.10, and 2050 max is $17.31, with min values of $1.85, $2.94, and $4.30 respectively. ROI grows from 0% in 2026 to 71% in 2030, 230.4% by 2040, and 467.3% by 2050, while sentiment shifts from NEUTRAL in the near term to BULLISH in the later years (2030 onward through 2050).
These estimates are not guarantees and are subject to uncertainty and market conditions.
Tap a question to reveal the answer.
Avg $2.60; Min $1.85; Max $3.95; ROI: 71%.
Forecasts show a bullish trajectory from 2028 onward, with Avg reaching $2.60 by 2030 and $8.62 by 2050, and Max up to $17.31 by 2050; ROI rises to 467.3% by 2050. 2026-2027 are NEUTRAL.
Yes. The 2034 max is $5.41 and the 2035 max is $6.82, indicating $5 is within the forecast range.
Avg $1.52; Min $1.21; Max $1.98; ROI: 0%.
Avg $8.62; Min $4.30; Max $17.31; ROI: 467.3%; Sentiment: BULLISH.
Autolus Therapeutics plc Community Discussion
0Share your Autolus Therapeutics plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.